Phaseline

Companies › Zhaoke (Guangzhou) Ophthalmology Pharmaceutical

Zhaoke (Guangzhou) Ophthalmology Pharmaceutical: clinical trials, targets and expected readouts

4 active drug programs in 34 registered trials: 15 Phase 2, 13 Phase 3, 4 Phase 4, 2 Phase 1; Ophthalmology, Gastroenterology, Other, Cardiovascular.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Atropine
Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor M2 antagonist
CHRM3, CHRM1, CHRM2Phase 3Myopia; Achalasia; Progressive Myopia; Focus on Axial Length …–
Cyclosporine
Cyclophilin A modulator
PPIAPhase 3Moderate to Severe Dry Eye; Meibomian Gland Dysfunction (MGD); Alopecia Areata(AA); Primary Autoimmune Hemolytic Anemia …–
BRIMOCHOL PF eye drops
Combined alpha-2A adrenergic agonist and muscarinic M3 receptor agonist
ADRA2A, M3Phase 2Presbyopia–
CARBACHOL PF eye drops
Muscarinic M3 receptor agonist (cholinergic miotic)
M3Phase 2Presbyopia–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06209281AtropinePhase 3MyopiaOphthalmologyAug 2023
NCT06209281AtropinePhase 3MyopiaOphthalmologyAug 2023
NCT03140358AtropinePhase 3MyopiaOphthalmologyDec 2024
NCT06209320AtropinePhase 3MyopiaOphthalmologyMar 2025
NCT06209320AtropinePhase 3MyopiaOphthalmologyMar 2025
NCT06431841AtropinePhase 4MyopiaOphthalmologyJun 2025
NCT06948357BRIMOCHOL PF eye dropsPhase 2PresbyopiaOphthalmologySep 2025
NCT06948357CARBACHOL PF eye dropsPhase 2PresbyopiaOphthalmologySep 2025
NCT06766357CyclosporinePhase 3Moderate to Severe Dry EyeOphthalmologyFeb 2026
NCT06523504AtropinePhase 1MyopiaOphthalmologyMar 2026
NCT06523504AtropinePhase 1MyopiaOphthalmologyMar 2026
NCT07456488AtropinePhase 2Focus on Axial LengthOtherApr 2026
NCT06200194AtropinePhase 2MyopiaOphthalmologyJul 2026
NCT07816224AtropinePhase 2EpiphoraOphthalmologyNov 2026
NCT05057468CyclosporinePhase 3Primary Autoimmune Hemolytic AnemiaHematologyNov 2026
NCT06708156AtropinePhase 3MyopiaOphthalmologyDec 2026
NCT06708156AtropinePhase 3MyopiaOphthalmologyDec 2026
NCT07224529CyclosporinePhase 4Meibomian Gland Dysfunction (MGD)OphthalmologyFeb 2027
NCT05946772CyclosporinePhase 2Takotsubo CardiomyopathyCardiovascularFeb 2027
NCT00544115CyclosporinePhase 2Chronic Myeloproliferative DisordersOncologyMar 2027
NCT07381556CyclosporinePhase 4Alopecia Areata(AA)ImmunologyNov 2027
NCT03865160AtropinePhase 2Myopia, ProgressiveOphthalmologyNov 2027
NCT03865160AtropinePhase 2Myopia, ProgressiveOphthalmologyNov 2027
NCT05153070CyclosporinePhase 2Type 1 DiabetesMetabolic and endocrineNov 2027
NCT00977977CyclosporinePhase 2Nephrotic SyndromeGenitourinaryDec 2027
NCT05815784AtropinePhase 2MyopiaOphthalmologyJan 2028
NCT07567040AtropinePhase 3MyopiaOphthalmologyMay 2028
NCT04641702AtropinePhase 4AchalasiaGastroenterologyDec 2028
NCT05667454AtropinePhase 3Progressive MyopiaOphthalmologyApr 2029
NCT05667454AtropinePhase 3Progressive MyopiaOphthalmologyApr 2029
NCT01624805CyclosporinePhase 2Aplastic AnemiaHematologyJun 2029
NCT07095894AtropinePhase 3MyopiaOphthalmologyJul 2029
NCT07874490CyclosporinePhase 2Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor ReceptorOncologyDec 2030
NCT04304820CyclosporinePhase 2Severe Aplastic AnemiaHematologyDec 2033

Targets

M3 (2) CHRM3 (1) CHRM1 (1) CHRM2 (1) PPIA (1) ADRA2A (1)

Companies with the same targets

Bristol-Myers Squibb AstraZeneca Ocus Innovation Ireland GSK Novartis BioTheraVision Chiesi Farmaceutici Anavex Life Sciences ACADIA Pharmaceuticals NSC-Therapeutics

Companies built like this

Ocus Innovation Ireland BioTheraVision Laboratoires Thea Opus Genetics Huons

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.